Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
This study evaluated the effectiveness of lenvatinib monotherapy for first-line treatment of unre- sectable hepatocellular carcinoma (uHCC) in a real-world setting.
This retrospective cohort study included patients who initiated lenvatinib monotherapy as first-line treatment for uHCC (n = 233). Clinical outcomes included provider-reported best response, progression-free survival (PFS) and overall survival (OS). PFS and OS were estimated using Kaplan–Meier methods.
Most patients (67.8%) were male. A total of 44.6% had Child-Pugh A and 39.1% had Child-Pugh B. Dose reductions were reported in 9%. Median PFS and OS were not reached. At 6 and 12 months, landmark PFS were 85.1 and 64.9%, respectively; landmark OS were 91.8 and 72.6%, respectively.